Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

被引：0
|
作者：
Schiff, David [1 ]
Sarkaria, Jann [2 ]
Decker, Paul [2 ]
Buckner, Jan [2 ]
Galanis, Evanthia [2 ]
Dancey, Janet [3 ]
Giannini, Caterina [2 ]
Brown, Paul [2 ]
Wiesenfeld, Martin [4 ]
Jaeckle, Kurt [5 ]
机构：
[1] Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA
[2] Mayo Clin, Rochester, MN USA
[3] Natl Canc Inst, Bethesda, MD USA
[4] Cedar Rapids Oncol Project, Cedar Rapids, IA USA
[5] Mayo Clin, Jacksonville, FL 32224 USA
来源：
NEURO-ONCOLOGY | 2007年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：518 / 518
页数：1
相关论文
共 50 条
  • [21] Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179
    Oza, A. M.
    Kollmannsberger, C.
    Hirte, H.
    Welch, S.
    Siu, L.
    Mazurka, J.
    Sederias, J.
    Doyle, L. A.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] GEMCITABINE COMBINED WITH THE MTOR INHIBITOR TEMSIROLIMUS(CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER (HE 3/07). A PHASE I STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
    Karavasilis, V.
    Pentheroudakis, G.
    Sgouros, J.
    Dimoudis, S. T.
    Varthalitis, I.
    Samantas, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 239 - 239
  • [23] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Susan M. Chang
    John Kuhn
    Patrick Wen
    Harry Greenberg
    David Schiff
    Charles Conrad
    Karen Fink
    H. Ian Robins
    Timothy Cloughesy
    Lisa De Angelis
    Jeffrey Razier
    Kenneth Hess
    Janet Dancey
    Michael D. Prados
    Investigational New Drugs, 2004, 22 : 427 - 435
  • [24] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Chang, SM
    Kuhn, J
    Wen, P
    Greenberg, H
    Schiff, D
    Conrad, C
    Fink, K
    Robins, HI
    Cloughesy, T
    De Angelis, L
    Razier, J
    Hess, K
    Dancey, J
    Prados, MD
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (04) : 427 - 435
  • [25] Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study.
    Sarantopoulos, J.
    Lenz, H.
    LoRusso, P.
    Shibata, S.
    Kummar, S.
    Mulkerin, D.
    Ramanathan, R. K.
    Mita, M. M.
    O'Rourke, P.
    Remick, S. C.
    Goel, S.
    Gutierrez, M.
    Ramalingam, S. S.
    Murgo, A.
    Davies, A. M.
    Mani, S.
    Boni, J.
    Shapiro, M.
    Ivy, S. P.
    Takimoto, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Chan, S
    Scheulen, ME
    Johnston, S
    Mross, K
    Cardoso, F
    Dittrich, C
    Eiermann, W
    Hess, D
    Morant, R
    Semiglazov, V
    Borner, M
    Salzberg, M
    Ostapenko, V
    Illiger, HJ
    Behringer, D
    Bardy-Bouxin, N
    Boni, J
    Kong, S
    Cincotta, M
    Moore, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5314 - 5322
  • [27] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
    Oza, A. M.
    Elit, L.
    Provencher, D.
    Biagi, J. J.
    Panasci, L.
    Sederias, J.
    Dancey, J. E.
    Tsao, S.
    Eisenhauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Anti-tumor activity of single-agent CCI-779 for relapsed mantle cell lymphoma: A phase II trial in the north central cancer treatment group.
    Witzig, T
    Geyer, S
    Ghobrial, I
    Inwards, D
    Fonseca, R
    Kaufmann, S
    Kurtin, P
    Colgan, J
    Morice, W
    Alberts, S
    Salim, M
    Rowland, K
    Dakhil, S
    Morton, R
    Stella, P
    BLOOD, 2004, 104 (11) : 40A - 40A
  • [29] Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D
    Sarkaria, J. N.
    Galanis, E.
    Gustafson, M. P.
    Dietz, A. B.
    Wu, W.
    Brown, P. D.
    Uhm, J. H.
    Giannini, C.
    Jaeckle, K. A.
    Buckner, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
    Galanis, Evanthia
    Jaeckle, Kurt A.
    Maurer, Matthew J.
    Reid, Joel M.
    Ames, Matthew M.
    Hardwick, James S.
    Reilly, John F.
    Loboda, Andrey
    Nebozhyn, Michael
    Fantin, Valeria R.
    Richon, Victoria M.
    Scheithauer, Bernd
    Giannini, Caterina
    Flynn, Patrick J.
    Moore, Dennis F., Jr.
    Zwiebel, James
    Buckner, Jan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 2052 - 2058
12345